Evidence to Date: Clinical Utility of Tremelimumab in the Treatment of Unresectable Hepatocellular Carcinoma
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Evidence to Date: Clinical Utility of Tremelimumab in the Treatment of Unresectable Hepatocellular Carcinoma
Authors
Keywords
-
Journal
Journal of Hepatocellular Carcinoma
Volume Volume 10, Issue -, Pages 1911-1922
Publisher
Informa UK Limited
Online
2023-10-27
DOI
10.2147/jhc.s395080
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Optimizing the Safe Washout Period for Liver Transplantation Following Immune Checkpoint Inhibitors with Atezolizumab, Nivolumab, or Pembrolizumab
- (2023) Fang-Cheng Kuo et al. TRANSPLANTATION PROCEEDINGS
- Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment
- (2022) Josep M. Llovet et al. CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY
- Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
- (2022) Ghassan K. Abou-Alfa et al. JOURNAL OF CLINICAL ONCOLOGY
- The Treatment Landscape of Advanced Hepatocellular Carcinoma
- (2022) Kit Man Wong et al. Current Oncology Reports
- Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial
- (2022) Sadahisa Ogasawara et al. BMJ Open
- Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study
- (2022) Beom Kyung Kim et al. Cancers
- LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)
- (2022) R.S. Finn et al. ANNALS OF ONCOLOGY
- 727TiP A randomised phase III study of tremelimumab (T) plus durvalumab (D) with or without lenvatinib combined with concurrent transarterial chemoembolisation (TACE) versus TACE alone in patients (pts) with locoregional hepatocellular carcinoma (HCC): EMERALD-3
- (2022) G.K. Abou-Alfa et al. ANNALS OF ONCOLOGY
- Adverse Reactions Associated With Immune Checkpoint Inhibitors and Bevacizumab: A Pharmacovigilance Analysis
- (2022) Tianqi Gu et al. INTERNATIONAL JOURNAL OF CANCER
- Cabozantinib: An Evolving Therapy for Hepatocellular Carcinoma
- (2021) Anthony B. El-Khoueiry et al. CANCER TREATMENT REVIEWS
- Case Report: Transarterial Chemoembolization in Combination With Tislelizumab Downstages Unresectable Hepatocellular Carcinoma Followed by Radical Salvage Resection
- (2021) Jiashuo Chao et al. Frontiers in Oncology
- Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study
- (2021) Robin Kate Kelley et al. JOURNAL OF CLINICAL ONCOLOGY
- Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period
- (2021) Guang-Hou Chen et al. TRANSPLANT IMMUNOLOGY
- Immune checkpoint inhibitor-related hepatotoxicity: A review
- (2021) Devika Remash et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Liver Transplantation for Hepatocellular Carcinoma after Downstaging or Bridging Therapy with Immune Checkpoint Inhibitors
- (2021) Qimeng Gao et al. Cancers
- BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
- (2021) Maria Reig et al. JOURNAL OF HEPATOLOGY
- Predictive factors for the development of proteinuria in cancer patients treated with bevacizumab, ramucirumab, and aflibercept: a single-institution retrospective analysis
- (2020) Yuko Kanbayashi et al. Scientific Reports
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib
- (2020) Thomas Yau et al. JAMA Oncology
- Systemic therapy of advanced hepatocellular carcinoma
- (2020) Peter R Galle et al. Future Oncology
- Lenvatinib: A Review in Hepatocellular Carcinoma
- (2019) Zaina T. Al-Salama et al. DRUGS
- From NASH to HCC: current concepts and future challenges
- (2019) Quentin M. Anstee et al. Nature Reviews Gastroenterology & Hepatology
- Immune checkpoint inhibitors for hepatocellular carcinoma
- (2019) Imane El Dika et al. CANCER
- Fatal Hepatic Necrosis after Nivolumab as a Bridge to Liver Transplant for HCC – Are Checkpoint Inhibitors Safe for the Pre‐Transplant Patient?
- (2019) Mina F. Nordness et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Bleeding risk in cancer patients treated with sorafenib: A meta-analysis of randomized controlled trials
- (2018) Fan Zhou et al. Journal of Cancer Research and Therapeutics
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents
- (2018) Daniel L. Suzman et al. LIVER INTERNATIONAL
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combinations of Bevacizumab With Cancer Immunotherapy
- (2018) Daniel S. Chen et al. CANCER JOURNAL
- Immune Checkpoint Inhibitor Toxicity
- (2018) David J. Palmieri et al. Current Oncology Reports
- The Role of Angiogenesis in Hepatocellular Carcinoma
- (2018) Michael A. Morse et al. CLINICAL CANCER RESEARCH
- Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017
- (2018) Gregory A Roth et al. LANCET
- Liver immunotolerance and hepatocellular carcinoma: Patho-physiological mechanisms and therapeutic perspectives
- (2017) Gaël S. Roth et al. EUROPEAN JOURNAL OF CANCER
- Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
- (2017) Austin G. Duffy et al. JOURNAL OF HEPATOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
- (2017) Guillermo De Velasco et al. Cancer Immunology Research
- Systematic review: colitis associated with anti-CTLA-4 therapy
- (2015) A. Gupta et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- The yin and yang of evasion and immune activation in HCC
- (2015) Oxana V. Makarova-Rusher et al. JOURNAL OF HEPATOLOGY
- TNM/Okuda/Barcelona/UNOS/CLIP International Multidisciplinary Classification of Hepatocellular Carcinoma: concepts, perspectives, and radiologic implications
- (2014) Silvana C. Faria et al. ABDOMINAL IMAGING
- Efficiency and Side Effects of Sorafenib Therapy for Advanced Hepatocellular Carcinoma: A Retrospective Study by the Anatolian Society of Medical Oncology
- (2014) Veli Berk et al. Asian Pacific Journal of Cancer Prevention
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
- (2014) L. Rahib et al. CANCER RESEARCH
- Prognosis of untreated hepatocellular carcinoma
- (2014) Edoardo G. Giannini et al. HEPATOLOGY
- Management of Sorafenib-Related Adverse Events: A Clinician’s Perspective
- (2014) Marcia S. Brose et al. SEMINARS IN ONCOLOGY
- Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.
- (2013) Robert J. Wong et al. HEPATOLOGY
- Efficacy, Safety, and Biomarkers of Single-Agent Bevacizumab Therapy in Patients with Advanced Hepatocellular Carcinoma
- (2012) V. Boige et al. ONCOLOGIST
- Efficacy and Safety of Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma: A Systematic Review of Phase II Trials
- (2012) Ping Fang et al. PLoS One
- Meta-analysis of dermatological toxicities associated with sorafenib
- (2011) L. Zhang et al. CLINICAL AND EXPERIMENTAL DERMATOLOGY
- Hepatocellular Carcinoma
- (2011) Hashem B. El-Serag NEW ENGLAND JOURNAL OF MEDICINE
- Sorafenib in the treatment of advanced hepatocellular carcinoma
- (2009) AliBen Mousa Saudi Journal of Gastroenterology
- Frequency and predictors ofde novo hepatocellular carcinoma in patients awaiting orthotopic liver transplantation during the model for end-stage liver disease era
- (2008) Carla W. Brady et al. LIVER TRANSPLANTATION
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now